APO Research
Talk to an analyst

APO RESEARCH · REPORT

Osimertinib

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Osimertinib Market Outlook and Growth Opportunities 2026

23 December 2025199 pages

Choose your research edition.

Industry ResearchOsimertinib Industry Research Report 2026118 pages · $2,950 USDIndustry Growth & TrendsGlobal Osimertinib Industry Growth and Trends Forecast to 203298 pages · $3,450 USDMarket StructureGlobal Osimertinib Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032188 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Osimertinib Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal Osimertinib Market Analysis and Forecast 2026-2032195 pages · $4,950 USD

Market perspective

The global Osimertinib market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Osimertinib is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Osimertinib is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Osimertinib is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Osimertinib market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Osimertinib market include Beacon Pharma, Drug International, Everest Pharmaceuticals, Incepta Pharmaceuticals Limited and AstraZeneca, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Osimertinib market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Osimertinib and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Osimertinib sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Osimertinib market size, projected growth trends, production technologies, key applications, and end-use industries.

Osimertinib Segment by Company

Beacon Pharma

Drug International

Everest Pharmaceuticals

Incepta Pharmaceuticals Limited

AstraZeneca

Osimertinib Segment by Type

80mg*30 Tablets

80mg*10 Tablets

40mg*30 Tablets

40mg*10 Tablets

Osimertinib Segment by Application

Locally Advanced NSCLC

Metastatic NSCLC

Others

Osimertinib Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Osimertinib status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Osimertinib market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Osimertinib significant trends, drivers, influence factors in global and regions.

6. To analyze Osimertinib competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Osimertinib market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Osimertinib and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Osimertinib.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Osimertinib market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Osimertinib industry.

Chapter 3: Detailed analysis of Osimertinib manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Osimertinib in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Osimertinib in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Osimertinib Industry Trends Table 2. Osimertinib Industry Drivers Table 3. Osimertinib Industry Opportunities and Challenges Table 4. Osimertinib Industry Restraints Table 5. Global Osimertinib Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Osimertinib Revenue Share by Company (2021-2026) Table 7. Global Osimertinib Sales Volume by Company (k pcs) & (2021-2026) Table 8. Global Osimertinib Sales Volume Share by Company (2021-2026) Table 9. Global Osimertinib Average Price (US$/pcs) of Company (2021-2026) Table 10. Global Osimertinib Company Ranking, (2024-2026) & (USD Million) Table 11. Global Osimertinib Key Company Manufacturing Base & Headquarters Table 12. Global Osimertinib Company, Product Type & Application Table 13. Global Osimertinib Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Osimertinib by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of 80mg*30 Tablets Table 18. Significant Companies of 80mg*10 Tablets Table 19. Significant Companies of 40mg*30 Tablets Table 20. Significant Companies of 40mg*10 Tablets Table 21. Global Osimertinib Sales Volume by Type 2021 VS 2025 VS 2032 (k pcs) Table 22. Global Osimertinib Sales Volume by Type (2021-2026) & (k pcs) Table 23. Global Osimertinib Sales Volume by Type (2027-2032) & (k pcs) Table 24. Global Osimertinib Sales Volume Share by Type (2021-2026) Table 25. Global Osimertinib Sales Volume Share by Type (2027-2032) Table 26. Global Osimertinib Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Osimertinib Sales Value by Type (2021-2026) & (US$ Million) Table 28. Global Osimertinib Sales Value by Type (2027-2032) & (US$ Million) Table 29. Global Osimertinib Sales Value Share by Type (2021-2026) Table 30. Global Osimertinib Sales Value Share by Type (2027-2032) Table 31. Significant Companies of Locally Advanced NSCLC Table 32. Significant Companies of Metastatic NSCLC Table 33. Significant Companies of Others Table 34. Global Osimertinib Sales Volume by Application 2021 VS 2025 VS 2032 (k pcs) Table 35. Global Osimertinib Sales Volume by Application (2021-2026) & (k pcs) Table 36. Global Osimertinib Sales Volume by Application (2027-2032) & (k pcs) Table 37. Global Osimertinib Sales Volume Share by Application (2021-2026) Table 38. Global Osimertinib Sales Volume Share by Application (2027-2032) Table 39. Global Osimertinib Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 40. Global Osimertinib Sales Value by Application (2021-2026) & (US$ Million) Table 41. Global Osimertinib Sales Value by Application (2027-2032) & (US$ Million) Table 42. Global Osimertinib Sales Value Share by Application (2021-2026) Table 43. Global Osimertinib Sales Value Share by Application (2027-2032) Table 44. Global Osimertinib Sales by Region: 2021 VS 2025 VS 2032 (k pcs) Table 45. Global Osimertinib Sales by Region (2021-2026) & (k pcs) Table 46. Global Osimertinib Sales Market Share by Region (2021-2026) Table 47. Global Osimertinib Sales by Region (2027-2032) & (k pcs) Table 48. Global Osimertinib Sales Market Share by Region (2027-2032) Table 49. Global Osimertinib Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 50. Global Osimertinib Sales Value by Region (2021-2026) & (US$ Million) Table 51. Global Osimertinib Sales Value Share by Region (2021-2026) Table 52. Global Osimertinib Sales Value by Region (2027-2032) & (US$ Million) Table 53. Global Osimertinib Sales Value Share by Region (2027-2032) Table 54. Global Osimertinib Market Average Price (US$/pcs) by Region (2021-2026) Table 55. Global Osimertinib Market Average Price (US$/pcs) by Region (2027-2032) Table 56. Global Osimertinib Sales by Country: 2021 VS 2025 VS 2032 (k pcs) Table 57. Global Osimertinib Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 58. Global Osimertinib Sales by Country (2021-2026) & (k pcs) Table 59. Global Osimertinib Sales Market Share by Country (2021-2026) Table 60. Global Osimertinib Sales by Country (2027-2032) & (k pcs) Table 61. Global Osimertinib Sales Market Share by Country (2027-2032) Table 62. Global Osimertinib Sales Value by Country (2021-2026) & (US$ Million) Table 63. Global Osimertinib Sales Value Market Share by Country (2021-2026) Table 64. Global Osimertinib Sales Value by Country (2027-2032) & (US$ Million) Table 65. Global Osimertinib Sales Value Market Share by Country (2027-2032) Table 66. Beacon Pharma Company Information Table 67. Beacon Pharma Business Overview Table 68. Beacon Pharma Osimertinib Sales (k pcs), Value (US$ Million), Price (US$/pcs) and Gross Margin (2021-2026) Table 69. Beacon Pharma Osimertinib Product Portfolio Table 70. Beacon Pharma Recent Development Table 71. Drug International Company Information Table 72. Drug International Business Overview Table 73. Drug International Osimertinib Sales (k pcs), Value (US$ Million), Price (US$/pcs) and Gross Margin (2021-2026) Table 74. Drug International Osimertinib Product Portfolio Table 75. Drug International Recent Development Table 76. Everest Pharmaceuticals Company Information Table 77. Everest Pharmaceuticals Business Overview Table 78. Everest Pharmaceuticals Osimertinib Sales (k pcs), Value (US$ Million), Price (US$/pcs) and Gross Margin (2021-2026) Table 79. Everest Pharmaceuticals Osimertinib Product Portfolio Table 80. Everest Pharmaceuticals Recent Development Table 81. Incepta Pharmaceuticals Limited Company Information Table 82. Incepta Pharmaceuticals Limited Business Overview Table 83. Incepta Pharmaceuticals Limited Osimertinib Sales (k pcs), Value (US$ Million), Price (US$/pcs) and Gross Margin (2021-2026) Table 84. Incepta Pharmaceuticals Limited Osimertinib Product Portfolio Table 85. Incepta Pharmaceuticals Limited Recent Development Table 86. AstraZeneca Company Information Table 87. AstraZeneca Business Overview Table 88. AstraZeneca Osimertinib Sales (k pcs), Value (US$ Million), Price (US$/pcs) and Gross Margin (2021-2026) Table 89. AstraZeneca Osimertinib Product Portfolio Table 90. AstraZeneca Recent Development Table 91. Key Raw Materials Table 92. Raw Materials Key Suppliers Table 93. Osimertinib Distributors List Table 94. Osimertinib Customers List Table 95. Research Programs/Design for This Report Table 96. Authors List of This Report Table 97. Secondary Sources Table 98. Primary Sources List of Figures Figure 1. Osimertinib Product Image Figure 2. Global Osimertinib Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Osimertinib Sales Value (2021-2032) & (US$ Million) Figure 4. Global Osimertinib Sales (2021-2032) & (k pcs) Figure 5. Global Osimertinib Sales Average Price (US$/pcs) & (2021-2032) Figure 6. Global Osimertinib Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. 80mg*30 Tablets Image Figure 10. 80mg*10 Tablets Image Figure 11. 40mg*30 Tablets Image Figure 12. 40mg*10 Tablets Image Figure 13. Global Osimertinib Sales Volume by Type (2021 VS 2025 VS 2032) & (k pcs) Figure 14. Global Osimertinib Sales Volume Share 2021 VS 2025 VS 2032 Figure 15. Global Osimertinib Sales Volume Share by Type (2021-2032) Figure 16. Global Osimertinib Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Osimertinib Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global Osimertinib Sales Value Share by Type (2021-2032) Figure 19. Locally Advanced NSCLC Image Figure 20. Metastatic NSCLC Image Figure 21. Others Image Figure 22. Global Osimertinib Sales Volume by Application (2021 VS 2025 VS 2032) & (k pcs) Figure 23. Global Osimertinib Sales Volume Share 2021 VS 2025 VS 2032 Figure 24. Global Osimertinib Sales Volume Share by Application (2021-2032) Figure 25. Global Osimertinib Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 26. Global Osimertinib Sales Value Share 2021 VS 2025 VS 2032 Figure 27. Global Osimertinib Sales Value Share by Application (2021-2032) Figure 28. Global Osimertinib Sales by Region: 2021 VS 2025 VS 2032 (k pcs) Figure 29. Global Osimertinib Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 30. Global Osimertinib Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 31. Global Osimertinib Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 32. North America Osimertinib Sales Value (2021-2032) & (US$ Million) Figure 33. North America Osimertinib Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Europe Osimertinib Sales Value (2021-2032) & (US$ Million) Figure 35. Europe Osimertinib Sales Value Share by Country (%), 2025 VS 2032 Figure 36. Asia-Pacific Osimertinib Sales Value (2021-2032) & (US$ Million) Figure 37. Asia-Pacific Osimertinib Sales Value Share by Country (%), 2025 VS 2032 Figure 38. South America Osimertinib Sales Value (2021-2032) & (US$ Million) Figure 39. South America Osimertinib Sales Value Share by Country (%), 2025 VS 2032 Figure 40. Middle East & Africa Osimertinib Sales Value (2021-2032) & (US$ Million) Figure 41. Middle East & Africa Osimertinib Sales Value Share by Country (%), 2025 VS 2032 Figure 42. USA Osimertinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. USA Osimertinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. USA Osimertinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Canada Osimertinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Canada Osimertinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Canada Osimertinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Mexico Osimertinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Mexico Osimertinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Mexico Osimertinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Germany Osimertinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Germany Osimertinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Germany Osimertinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. France Osimertinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. France Osimertinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. France Osimertinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. U.K. Osimertinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. U.K. Osimertinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. U.K. Osimertinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Italy Osimertinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Italy Osimertinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Italy Osimertinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Spain Osimertinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Spain Osimertinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Spain Osimertinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Russia Osimertinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Russia Osimertinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Russia Osimertinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Netherlands Osimertinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Netherlands Osimertinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Netherlands Osimertinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. Nordic Countries Osimertinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. Nordic Countries Osimertinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. Nordic Countries Osimertinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. China Osimertinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. China Osimertinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. China Osimertinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Japan Osimertinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Japan Osimertinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Japan Osimertinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. South Korea Osimertinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. South Korea Osimertinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. South Korea Osimertinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. India Osimertinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. India Osimertinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. India Osimertinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Australia Osimertinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Australia Osimertinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Australia Osimertinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Southeast Asia Osimertinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Southeast Asia Osimertinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Southeast Asia Osimertinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Brazil Osimertinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Brazil Osimertinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Brazil Osimertinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Argentina Osimertinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Argentina Osimertinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Argentina Osimertinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Chile Osimertinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Chile Osimertinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Chile Osimertinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Colombia Osimertinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Colombia Osimertinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Colombia Osimertinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Peru Osimertinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Peru Osimertinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Peru Osimertinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Osimertinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Saudi Arabia Osimertinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Saudi Arabia Osimertinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Israel Osimertinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Israel Arabia Osimertinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Israel Arabia Osimertinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. UAE Osimertinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. UAE Osimertinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. UAE Osimertinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Turkey Osimertinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Turkey Osimertinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Turkey Osimertinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Iran Osimertinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Iran Osimertinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Iran Osimertinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Egypt Osimertinib Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 124. Egypt Osimertinib Sales Value Share by Type, 2025 VS 2032 & (%) Figure 125. Egypt Osimertinib Sales Value Share by Application, 2025 VS 2032 & (%) Figure 126. Osimertinib Value Chain Figure 127. Manufacturing Cost Structure Figure 128. Osimertinib Sales Mode & Process Figure 129. Direct Comparison with Distribution Share Figure 130. Distributors Profiles Figure 131. Years Considered Figure 132. Research Process Figure 133. Key Executives Interviewed

Scope & coverage.

Types
  • 80mg*30 Tablets
  • 80mg*10 Tablets
  • 40mg*30 Tablets
  • 40mg*10 Tablets
Applications
  • Locally Advanced NSCLC
  • Metastatic NSCLC
  • Others
Companies covered
  • Beacon Pharma
  • Drug International
  • Everest Pharmaceuticals
  • Incepta Pharmaceuticals Limited
  • AstraZeneca

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Osimertinib Sales Value (2021-2032)
  4. 1.2.2 Global Osimertinib Sales Volume (2021-2032)
  5. 1.2.3 Global Osimertinib Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Osimertinib Market Dynamics
  1. 2.1 Osimertinib Industry Trends
  2. 2.2 Osimertinib Industry Drivers
  3. 2.3 Osimertinib Industry Opportunities and Challenges
  4. 2.4 Osimertinib Industry Restraints
3 Osimertinib Market by Company
  1. 3.1 Global Osimertinib Company Revenue Ranking in 2025
  2. 3.2 Global Osimertinib Revenue by Company (2021-2026)
  3. 3.3 Global Osimertinib Sales Volume by Company (2021-2026)
  4. 3.4 Global Osimertinib Average Price by Company (2021-2026)
  5. 3.5 Global Osimertinib Company Ranking (2024-2026)
  6. 3.6 Global Osimertinib Company Manufacturing Base and Headquarters
  7. 3.7 Global Osimertinib Company Product Type and Application
  8. 3.8 Global Osimertinib Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Osimertinib Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Osimertinib Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Osimertinib Market by Type
  1. 4.1 Osimertinib Type Introduction
  2. 4.1.1 80mg*30 Tablets
  3. 4.1.2 80mg*10 Tablets
  4. 4.1.3 40mg*30 Tablets
  5. 4.1.4 40mg*10 Tablets
  6. 4.2 Global Osimertinib Sales Volume by Type
  7. 4.2.1 Global Osimertinib Sales Volume by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Osimertinib Sales Volume by Type (2021-2032)
  9. 4.2.3 Global Osimertinib Sales Volume Share by Type (2021-2032)
  10. 4.3 Global Osimertinib Sales Value by Type
  11. 4.3.1 Global Osimertinib Sales Value by Type (2021 VS 2025 VS 2032)
  12. 4.3.2 Global Osimertinib Sales Value by Type (2021-2032)
  13. 4.3.3 Global Osimertinib Sales Value Share by Type (2021-2032)
5 Osimertinib Market by Application
  1. 5.1 Osimertinib Application Introduction
  2. 5.1.1 Locally Advanced NSCLC
  3. 5.1.2 Metastatic NSCLC
  4. 5.1.3 Others
  5. 5.2 Global Osimertinib Sales Volume by Application
  6. 5.2.1 Global Osimertinib Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Osimertinib Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Osimertinib Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Osimertinib Sales Value by Application
  10. 5.3.1 Global Osimertinib Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Osimertinib Sales Value by Application (2021-2032)
  12. 5.3.3 Global Osimertinib Sales Value Share by Application (2021-2032)
6 Osimertinib Regional Sales and Value Analysis
  1. 6.1 Global Osimertinib Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Osimertinib Sales by Region (2021-2032)
  3. 6.2.1 Global Osimertinib Sales by Region: 2021-2026
  4. 6.2.2 Global Osimertinib Sales by Region (2027-2032)
  5. 6.3 Global Osimertinib Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Osimertinib Sales Value by Region (2021-2032)
  7. 6.4.1 Global Osimertinib Sales Value by Region: 2021-2026
  8. 6.4.2 Global Osimertinib Sales Value by Region (2027-2032)
  9. 6.5 Global Osimertinib Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Osimertinib Sales Value (2021-2032)
  12. 6.6.2 North America Osimertinib Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Osimertinib Sales Value (2021-2032)
  15. 6.7.2 Europe Osimertinib Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Osimertinib Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Osimertinib Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Osimertinib Sales Value (2021-2032)
  21. 6.9.2 South America Osimertinib Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Osimertinib Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Osimertinib Sales Value Share by Country, 2025 VS 2032
7 Osimertinib Country-level Sales and Value Analysis
  1. 7.1 Global Osimertinib Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Osimertinib Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Osimertinib Sales by Country (2021-2032)
  4. 7.3.1 Global Osimertinib Sales by Country (2021-2026)
  5. 7.3.2 Global Osimertinib Sales by Country (2027-2032)
  6. 7.4 Global Osimertinib Sales Value by Country (2021-2032)
  7. 7.4.1 Global Osimertinib Sales Value by Country (2021-2026)
  8. 7.4.2 Global Osimertinib Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Osimertinib Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Osimertinib Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Osimertinib Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Osimertinib Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Osimertinib Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Osimertinib Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Osimertinib Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Osimertinib Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Osimertinib Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Osimertinib Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Osimertinib Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Osimertinib Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Osimertinib Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Osimertinib Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Osimertinib Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Osimertinib Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Osimertinib Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Osimertinib Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Osimertinib Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Osimertinib Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Osimertinib Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Osimertinib Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Osimertinib Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Osimertinib Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Osimertinib Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Osimertinib Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Osimertinib Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Osimertinib Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Osimertinib Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Osimertinib Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Osimertinib Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Osimertinib Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Osimertinib Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Osimertinib Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Osimertinib Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Osimertinib Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Osimertinib Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Osimertinib Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Osimertinib Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Osimertinib Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Osimertinib Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Osimertinib Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Osimertinib Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Osimertinib Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Osimertinib Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Osimertinib Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Osimertinib Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Osimertinib Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Osimertinib Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Osimertinib Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Osimertinib Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Osimertinib Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Osimertinib Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Osimertinib Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Osimertinib Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Osimertinib Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Osimertinib Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Osimertinib Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Osimertinib Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Osimertinib Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Osimertinib Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Osimertinib Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Osimertinib Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Osimertinib Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Osimertinib Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Osimertinib Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Osimertinib Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Osimertinib Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Osimertinib Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Osimertinib Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Osimertinib Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Osimertinib Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Osimertinib Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Osimertinib Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Osimertinib Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Osimertinib Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Osimertinib Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Osimertinib Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Osimertinib Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Osimertinib Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Osimertinib Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Osimertinib Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Osimertinib Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Osimertinib Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Beacon Pharma
  2. 8.1.1 Beacon Pharma Company Information
  3. 8.1.2 Beacon Pharma Business Overview
  4. 8.1.3 Beacon Pharma Osimertinib Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Beacon Pharma Osimertinib Product Portfolio
  6. 8.1.5 Beacon Pharma Recent Developments
  7. 8.2 Drug International
  8. 8.2.1 Drug International Company Information
  9. 8.2.2 Drug International Business Overview
  10. 8.2.3 Drug International Osimertinib Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Drug International Osimertinib Product Portfolio
  12. 8.2.5 Drug International Recent Developments
  13. 8.3 Everest Pharmaceuticals
  14. 8.3.1 Everest Pharmaceuticals Company Information
  15. 8.3.2 Everest Pharmaceuticals Business Overview
  16. 8.3.3 Everest Pharmaceuticals Osimertinib Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Everest Pharmaceuticals Osimertinib Product Portfolio
  18. 8.3.5 Everest Pharmaceuticals Recent Developments
  19. 8.4 Incepta Pharmaceuticals Limited
  20. 8.4.1 Incepta Pharmaceuticals Limited Company Information
  21. 8.4.2 Incepta Pharmaceuticals Limited Business Overview
  22. 8.4.3 Incepta Pharmaceuticals Limited Osimertinib Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Incepta Pharmaceuticals Limited Osimertinib Product Portfolio
  24. 8.4.5 Incepta Pharmaceuticals Limited Recent Developments
  25. 8.5 AstraZeneca
  26. 8.5.1 AstraZeneca Company Information
  27. 8.5.2 AstraZeneca Business Overview
  28. 8.5.3 AstraZeneca Osimertinib Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 AstraZeneca Osimertinib Product Portfolio
  30. 8.5.5 AstraZeneca Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Osimertinib Value Chain Analysis
  2. 9.1.1 Osimertinib Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Osimertinib Sales Mode & Process
  6. 9.2 Osimertinib Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Osimertinib Distributors
  9. 9.2.3 Osimertinib Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst